Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.
It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure.
In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures.
It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease.
Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -0.49 Decreased by -28.95% | -0.46 Decreased by -6.52% |
| Mar 31, 25 | -0.42 Decreased by -13.51% | -0.45 Increased by +6.67% |
| Nov 13, 24 | -0.41 Decreased by -7.89% | -0.44 Increased by +7.34% |
| Aug 13, 24 | -0.45 Decreased by -28.57% | -0.40 Decreased by -12.50% |
| May 13, 24 | -0.38 Increased by +5.00% | -0.40 Increased by +5.00% |
| Mar 27, 24 | -0.37 Decreased by -362.50% | -0.38 Increased by +2.63% |
| Nov 13, 23 | -0.38 Decreased by -660.00% | -0.39 Increased by +2.56% |
| Aug 10, 23 | -0.35 Decreased by -775.00% | -0.41 Increased by +14.63% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 868.00 K Increased by +40.00% | -18.75 M Decreased by -39.31% | Decreased by -2.16 K% Increased by +0.49% |
| Dec 31, 24 | 253.00 K Decreased by -3.44% | -16.16 M Decreased by -26.03% | Decreased by -6.39 K% Decreased by -30.52% |
| Sep 30, 24 | 987.00 K Increased by +135.56% | -15.43 M Decreased by -15.85% | Decreased by -1.56 K% Increased by +50.82% |
| Jun 30, 24 | 778.00 K Decreased by -14.97% | -15.98 M Decreased by -32.66% | Decreased by -2.05 K% Decreased by -56.02% |
| Mar 31, 24 | 620.00 K Decreased by -46.74% | -13.46 M Decreased by -23.06% | Decreased by -2.17 K% Decreased by -131.04% |
| Dec 31, 23 | 262.00 K Decreased by -76.25% | -12.82 M Decreased by -1.36 K% | Decreased by -4.89 K% Decreased by -6.06 K% |
| Sep 30, 23 | 419.00 K Decreased by -63.97% | -13.32 M Decreased by -1.84 K% | Decreased by -3.18 K% Decreased by -5.29 K% |
| Jun 30, 23 | 915.00 K Increased by +128.18% | -12.05 M Decreased by -53.51% | Decreased by -1.32 K% Increased by +32.72% |